5-Alpha-Reductase Inhibitors
Key Points
- 5-alpha-reductase inhibitors (finasteride, dutasteride) reduce conversion of testosterone to dihydrotestosterone and gradually shrink prostate volume.
- Symptom improvement is delayed; meaningful response often requires several weeks, with maximal benefit around 6 months.
- Class therapy can lower PSA values by about 50%, so PSA interpretation must account for medication effect.
- Common adverse effects include erectile dysfunction, reduced libido/ejaculatory volume, dizziness, and gynecomastia.
- Finasteride and dutasteride are contraindicated in pregnancy exposure contexts.
- Crushed or broken tablets should not be handled by pregnant individuals or those who may become pregnant.
Mechanism of Action
5-alpha-reductase inhibitors block enzymatic conversion of testosterone to dihydrotestosterone (DHT), the androgen that drives prostate growth in BPH pathways. With sustained treatment, prostate size decreases and urinary-flow obstruction can improve.
Common Agents and Typical Dosing
| Drug | Typical BPH Dose |
|---|---|
| Finasteride (Proscar) | 5 mg PO once daily |
| Dutasteride (Avodart) | 0.5 mg PO once daily |
Nursing Considerations
- Explain delayed onset and reinforce adherence despite slow early response.
- Track urinary symptom trend and postvoid status over follow-up visits.
- Interpret PSA cautiously because class therapy reduces PSA values.
- Monitor for dizziness and orthostatic symptoms, especially when combined with alpha-blockers.
- Review fertility/sexual-function concerns and provide counseling for adverse effects.
- Reinforce pregnancy-exposure precautions during medication handling.
- In transgender feminizing regimens, recognize finasteride as a lower-potency antiandrogen option when spironolactone is not tolerated or not feasible.
Adverse Effects and Contraindications
Common adverse effects:
- Erectile dysfunction
- Decreased libido and ejaculatory volume
- Gynecomastia
- Dizziness, weakness, orthostatic symptoms
- Ejaculation and orgasm disorders; possible male infertility reports
Potential higher-risk concerns:
- Breast changes including neoplasm concern
- Increased detection of high-grade prostate-cancer patterns in some long-term pathways
Contraindications:
- Hypersensitivity
- Pregnancy exposure pathways
Patient Education
- Take medication consistently each day and keep follow-up appointments.
- Do not stop medication early because maximal benefit may take months.
- Change positions slowly to reduce postural dizziness/fall risk.
- Report breast changes, severe dizziness, persistent sexual dysfunction, or worsening urinary symptoms.
- Keep tablets intact; avoid exposing pregnant household contacts to crushed or broken tablets.
Related Concepts
- benign-prostatic-hyperplasia - Core indication and symptom-monitoring context.
- alpha-blockers - Common combination strategy with additive hypotension risk.
- erectile-dysfunction - Sexual side effects can affect adherence and quality of life.
- postural-hypotension - Orthostatic safety monitoring in combination regimens.
Self-Check
- Why do 5-alpha-reductase inhibitors require longer treatment duration before maximal symptom benefit?
- How should PSA trends be interpreted in clients taking finasteride or dutasteride?
- Which patient-education points reduce household pregnancy-exposure risk?